Peroxisome Proliferator-activated Receptor (PPAR) Gene Profiling Uncovers Insulin-like Growth Factor-1 as a PPARα Target Gene in Cardioprotection*
暂无分享,去创建一个
L. D. de Windt | M. van Bilsen | H. el Azzouzi | S. Leptidis | M. Bourajjaj | Anne-Sophie Armand | R. van der Nagel | P. A. da Costa Martins | Roel van der Nagel | Marc van Bilsen | Hamid el Azzouzi | Stefanos Leptidis | Meriem Bourajjaj | Anne-Sophie Armand | Paula A Da Costa Martins | Leon J De Windt
[1] Bernd Zetsche,et al. Local Atrial Natriuretic Peptide Signaling Prevents Hypertensive Cardiac Hypertrophy in Endothelial Nitric-oxide Synthase-deficient Mice* , 2005, Journal of Biological Chemistry.
[2] A. M. Lefer,et al. Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[3] L. D. de Windt,et al. Activation of PPARδ inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts , 2007 .
[4] T. Casavant,et al. Gene expression profiling of potential PPARγ target genes in mouse aorta , 2004 .
[5] Atsushi Ono,et al. Profiling of gene expression in rat liver and rat primary cultured hepatocytes treated with peroxisome proliferators. , 2006, The Journal of toxicological sciences.
[6] C. Yeh,et al. Inhibition of NF-κB Activation Can Attenuate Ischemia/Reperfusion-Induced Contractility Impairment Via Decreasing Cardiomyocytic Proinflammatory Gene Up-Regulation and Matrix Metalloproteinase Expression , 2005, Journal of cardiovascular pharmacology.
[7] M. Rao,et al. Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. , 1993, The Journal of biological chemistry.
[8] Michael D. Schneider,et al. Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage. , 2007, Cardiovascular research.
[9] G. FitzGerald,et al. Oxidative stress and cardiovascular injury: Part II: animal and human studies. , 2003, Circulation.
[10] G. Dorn,et al. Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. , 2007, Physiology.
[11] K. Kinzler,et al. PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999, Cell.
[12] M. Chandler,et al. Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure. , 2006, American journal of physiology. Heart and circulatory physiology.
[13] Paul A. Overbeek,et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice , 2000, Nature Medicine.
[14] Danielle G. Lemay,et al. Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics s⃞ Published, JLR Papers in Press, April 3, 2006. , 2006, Journal of Lipid Research.
[15] D. Kelly,et al. The PPAR trio: regulators of myocardial energy metabolism in health and disease. , 2008, Journal of molecular and cellular cardiology.
[16] Vincenzo Lionetti,et al. Chronic Activation of Peroxisome Proliferator-Activated Receptor-α with Fenofibrate Prevents Alterations in Cardiac Metabolic Phenotype without Changing the Onset of Decompensation in Pacing-Induced Heart Failure , 2007, Journal of Pharmacology and Experimental Therapeutics.
[17] E. Olson,et al. Conditional Expression of SV40 T-antigen in Mouse Cardiomyocytes Facilitates an Inducible Switch from Proliferation to Differentiation* 210 , 2003, The Journal of Biological Chemistry.
[18] P. Doevendans,et al. Downregulation of Apoptosis-Inducing Factor in Harlequin Mutant Mice Sensitizes the Myocardium to Oxidative Stress–Related Cell Death and Pressure Overload–Induced Decompensation , 2005, Circulation research.
[19] Arnaud Pillon,et al. Differential responses of PPARα, PPARδ, and PPARγ reporter cell lines to selective PPAR synthetic ligands , 2005 .
[20] M. Bilsen,et al. Metabolic remodelling of the failing heart: beneficial or detrimental? , 2008 .
[21] G. J. van der Vusse,et al. Peroxisome proliferator‐activated receptors and inflammation: take it to heart , 2007, Acta physiologica.
[22] B. Spiegelman,et al. Differential activation of adipogenesis by multiple PPAR isoforms. , 1996, Genes & development.
[23] X. Wehrens,et al. NFATc2 Is a Necessary Mediator of Calcineurin-dependent Cardiac Hypertrophy and Heart Failure* , 2008, Journal of Biological Chemistry.
[24] H. Taegtmeyer,et al. Reactivation of Peroxisome Proliferator-activated Receptor α Is Associated with Contractile Dysfunction in Hypertrophied Rat Heart* , 2001, The Journal of Biological Chemistry.
[25] J. Comella,et al. Activation of Phosphatidylinositol 3‐Kinase, but Not Extracellular‐Regulated Kinases, Is Necessary to Mediate Brain‐Derived Neurotrophic Factor‐Induced Motoneuron Survival , 1999, Journal of neurochemistry.
[26] G. Reach,et al. PPAR-α–Null Mice Are Protected From High-Fat Diet–Induced Insulin Resistance , 2001 .
[27] P. Libby,et al. PPARα Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells , 1999 .
[28] J. Ross,et al. Loss of a gp130 Cardiac Muscle Cell Survival Pathway Is a Critical Event in the Onset of Heart Failure during Biomechanical Stress , 1999, Cell.
[29] A. M. Lefer,et al. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. , 1995, Circulation.
[30] Lei Wang,et al. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. , 1998, Circulation research.
[31] R. Evans,et al. Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[32] G. Condorelli,et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling , 2010, Nature Cell Biology.
[33] P. Anversa,et al. Insulin-like growth factor-1 attenuates the detrimental impact of nonocclusive coronary artery constriction on the heart. , 1999, Circulation research.
[34] Xianlin Han,et al. A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: Modulation by dietary fat content , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[35] J. Ward,et al. Growth, Adipose, Brain, and Skin Alterations Resulting from Targeted Disruption of the Mouse Peroxisome Proliferator-Activated Receptor β(δ) , 2000, Molecular and Cellular Biology.
[36] D. Haro,et al. Functional interaction between peroxisome proliferator-activated receptors-α and Mef-2C on human carnitine palmitoyltransferase 1β (CPT1β) gene activation , 2004 .
[37] Xianlin Han,et al. Nuclear receptors PPARβ/δ and PPARα direct distinct metabolic regulatory programs in the mouse heart , 2007 .
[38] P. Doevendans,et al. Myocyte apoptosis in heart failure. , 2005, Cardiovascular research.
[39] G. J. van der Vusse,et al. Peroxisome Proliferator-Activated Receptor (PPAR) &agr; and PPAR&bgr;/&dgr;, but not PPAR&ggr;, Modulate the Expression of Genes Involved in Cardiac Lipid Metabolism , 2003, Circulation research.
[40] H. Vidal,et al. The Regulation of Uncoupling Protein-2 Gene Expression by ω-6 Polyunsaturated Fatty Acids in Human Skeletal Muscle Cells Involves Multiple Pathways, Including the Nuclear Receptor Peroxisome Proliferator-activated Receptor β* , 2001, The Journal of Biological Chemistry.
[41] P. Doevendans,et al. MEF2 Activates a Genetic Program Promoting Chamber Dilation and Contractile Dysfunction in Calcineurin-Induced Heart Failure , 2006, Circulation.
[42] Michael D. Schneider,et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-δ deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy , 2004, Nature Medicine.
[43] P. Doevendans,et al. Requirement of Nuclear Factor of Activated T-cells in Calcineurin-mediated Cardiomyocyte Hypertrophy* , 2002, The Journal of Biological Chemistry.